Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved a new indication for DARZALEX or daratumumab subcutaneous formulation as monotherapy for the treatment of adult patients with smouldering multiple myeloma at high-risk of developing multiple myeloma.
Separately, Janssen-Cilag announced that the European Commission has approved an indication extension of IMBRUVICA or ibrutinib in frontline mantle cell lymphoma. The approval is for ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone alternating with R-DHAP without ibrutinib, followed by ibrutinib monotherapy, for the treatment of adult patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.